The influence of CYP enzymes and ABCB1 on treatment outcomes in schizophrenia: association of CYP1A2 activity with adverse effects

Abstract

Aim: Genetic variants on metabolic and transport enzymes are good candidates to explain inter-individual differences in response to antipsychotics. The aim of this study is to evaluate and compare the influence of the CYP2D6, CYPC19, CYP1A2 and ABCB1 variants on plasma levels, treatment response and side effects of antipsychotics.

Methods: Twenty polymorphisms in selected genes were genotyped in 318 patients diagnosed with schizophrenia, schizoaffective or delusional disorder treated with antipsychotics (clozapine, olanzapine, paliperidone, risperidone, aripiprazole and quetiapine). Plasma drug levels were determined after 6 weeks of treatment. The Positive and Negative Symptoms Scale (PANSS) and UKU scale of side effects were recorded at baseline and after 12 weeks of treatment. The effect of gene variants on plasma drug levels, treatment response and adverse effects were examined by multinomial regression.

Results:CYP1A2 was found to be associated with psychic side effects (P = 0.02), with variants predicting higher enzyme activity associated with lower adverse effects, and was the strongest predictor for this adverse effect of all the studied factors. Functional variants in CYP genes were associated with plasma level differences, with higher activity variants associated with lower plasma levels. No association with improvement of the condition, as measured by the PANSS score, was found in this study.

Conclusion: The results suggest that increased CYP1A2 activity protects against psychic side effects. Few studies have evaluated the impact of genetic factors on treatment response or side effects, and only in relation to a selection of adverse reactions. These results are a step towards better understanding of the factors behind the different aspects of clinical outcomes, such as various adverse effects.

Keywords

Pharmacogenetics / antipsychotics / CYP1A2 / CYP2C19 / CYP2D6 / ABCB1 / drug response / adverse drug reactions

References

[1] IversenTSJ,DiesetI,MørchR.Side effect burden of antipsychotic drugs in real life-Impact of gender and polypharmacy..Prog Neuropsychopharmacol Biol Psychiatry2018;82:263-71

[2] McCutcheonR,D’AmbrosioE,GobjilaC.Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia..Acta Psychiatr Scand2018;137:39-46 PMCID:PMC5734612

[3] JukicMM,HaslemoT,Ingelman-SundbergM.Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study..Lancet Psychiatry2019;6:418-26

[4] RuanCJ,WangCY,SunC.Clozapine metabolism in east Asians and caucasians: a pilot exploration of the prevalence of poor metabolizers and a systematic review..J Clin Psychopharmacol2019;39:135-44

[5] KurylevAA,AndreevBV,LimankinOV.The combined effect of CYP2D6 and DRD2 Taq1A polymorphisms on the antipsychotics daily doses and hospital stay duration in schizophrenia inpatients (observational naturalistic study)..Psychiatr Danub2018;30:157-63

[6] MasS,AlvarezS,BernardoM.Intuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes..Pharmacogenomics J2012;12:255-9

[7] KirchheinerJ,SchömigE.Contribution of allelic variations in transporters to the phenotype of drug response..J Psychopharmacol2006;20:27-32

[8] FrommMF.Importance of P-glycoprotein at blood-tissue barriers..Trends Pharmacol Sci2004;25:423-9

[9] BruckmuellerH,KählerM,OstrowskiM.Clinically relevant multidrug transporters are regulated by microRNAs along the human intestine..Mol Pharm2017;14:2245-53

[10] van der WeideK.The influence of the CYP3A4*22 polymorphism and CYP2D6 polymorphisms on serum concentrations of aripiprazole, haloperidol, pimozide, and risperidone in psychiatric patients..J Clin Psychopharmacol2015;35:228-36

[11] FilipceA,NestorovskaAK,BrezovskaK.Evaluation of correlation between the pharmacogenetic profiles of risperidone treated psychiatry patients with plasma and urine concentration of risperidone and its active moiety 9-OH rsperidone determined with optimized bioanalytical LC method..Pril (Makedon Akad Nauk Umet Odd Med Nauki)2018;39:97-106

[12] BakkenGV,HermannM.Impact of genetic variability in CYP2D6, CYP3A5, and ABCB1 on serum concentrations of quetiapine and N-desalkylquetiapine in psychiatric patients..Ther Drug Monit2015;37:256-61

[13] SuzukiT,NakamuraA,NagaiG.Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia..Ther Drug Monit2014;36:651-5

[14] González-VacarezzaN,Peñas-LledóEM,Estévez-CarrizoFE.MDR-1 genotypes and quetiapine pharmacokinetics in healthy volunteers..Drug Metabol Drug Interact2013;28:163-6

[15] van de BiltMT,OjopiEP,LochAA.Cytochrome P450 genotypes are not associated with refractoriness to antipsychotic treatment..Schizophr Res2015;168:587-8

[16] AlmogueraB,Lopez-CastromanJ,Vaquero-LorenzoC.CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment..Pharmacogenet Genomics2013;23:627-30

[17] PapazisisG,SarrigiannidisA,AntoniadisD.ABCB1 and CYP2D6 polymorphisms and treatment response of psychotic patients in a naturalistic setting..Hum Psychopharmacol2018;33:

[18] VijayanNN,BalanS,NairCM.Antipsychotic drug dosage and therapeutic response in schizophrenia is influenced by ABCB1 genotypes: a study from a south Indian perspective..Pharmacogenomics2012;13:1119-27

[19] KastelicM,PlesnicarBK,MandelliL.MDR1 gene polymorphisms and response to acute risperidone treatment..Prog Neuropsychopharmacol Biol Psychiatry2010;34:387-92

[20] SuzukiY,FukuiN,WatanabeJ.Effect of risperidone metabolism and P-glycoprotein gene polymorphism on QT interval in patients with schizophrenia..Pharmacogenomics J2014;14:452-6

[21] GrădinaruR,NussbaumL,PuiuM.Impact of the CYP2D6 phenotype on hyperprolactinemia development as an adverse event of treatment with atypical antipsychotic agents in pediatric patients..Ir J Med Sci2019;188:1417-22

[22] IvanovaSA,VyalovaNM,PozhidaevIV.CYP1A2 and CYP2D6 gene polymorphisms in schizophrenic patients with neuroleptic drug-induced side effects..Bull Exp Biol Med2016;160:687-90

[23] HattoriS,KishidaI,ShiraishiY.Effects of ABCB1 gene polymorphisms on autonomic nervous system activity during atypical antipsychotic treatment in schizophrenia..BMC Psychiatry2018;18:231 PMCID:PMC6050702

[24] ArranzMJ,Perez-BlancoJ,GutierrezB.A pharmacogenetic intervention for the improvement of the safety profile of antipsychotic treatments..Transl Psychiatry2019;9:177 PMCID:PMC6658489

[25] FrahnertC,GrasmäderK.Analysis of eighteen antidepressants, four atypical antipsychotics and active metabolites in serum by liquid chromatography: a simple tool for therapeutic drug monitoring..J Chromatogr B2003;794:35-47

[26] LeuchtS,HeresS,FurukawaT.Dose equivalents for second-generation antipsychotic drugs: the classical mean dose method..Schizophr Bull2015;41:1397-402 PMCID:PMC4601707

[27] KaySR,OplerLA.The positive and negative syndrome scale (PANSS) for schizophrenia..Schizophrenia Bull1987;13:261-76

[28] Kimchi-SarfatyC,KimIW,CalcagnoAM.A “silent” polymorphism in the MDR1 gene changes substrate specificity..Science2007;318:1382-3

[29] LingjaerdeO,BechP,ElgenK.The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients..Acta Psychiatr Scand Suppl1987;334:1-100

[30] GaedigkA,PearceRE,KennedyMJ.The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype..Clin Pharmacol Ther2008;83:234-42

[31] CaudleKE,FreimuthRR,BurlisonJD.Standardizing terms for clinical pharmacogenetic test results: consensus terms from the clinical pharmacogenetics implementation consortium (CPIC)..Genet Med2017;19:215-223 PMCID:PMC5253119

[32] CaudleKE,Whirl-CarrilloM,HaidarCE.Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the clinical pharmacogenetics implementation consortium and dutch pharmacogenetics working group..Clin Transl Sci2020;13:116-24 PMCID:PMC6951851

[33] JovanovićN,LovrićM,JakovljevićM.The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone..Eur J Clin Pharmacol2010;66:1109-17

[34] LisbethP,KristofM,ManuelM.Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol..Eur J Clin Pharmacol2016;72:175-84

[35] CzerwenskyF,SteimerW.CYP1A2*1D and *1F polymorphisms have a significant impact on olanzapine serum concentrations..Ther Drug Monit2015;37:152-60

[36] JaquenoudSirot E,MorenaGP,OnedaB.ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine..J Clin Psychopharmacol2009;29:319-26

[37] TóthK,SirokD,KissÁ.Potential role of patients’ CYP3A-status in clozapine pharmacokinetics..Int J Neuropsychopharmacol2017;20:529-37 PMCID:PMC5492788

[38] HuangHC,WuLS,LeeSM.Cigarette smoking has a differential effect on the plasma level of clozapine in Taiwanese schizophrenic patients associated with the CYP1A2 gene-163A/C single nucleotide polymorphism..Psychiatr Genet2016;26:172-7

[39] RafanielloC,BernardiFF,CheliS.The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions..Pharmacogenomics J2018;18:422-30

[40] NikischG,OnedaB,WeisserH.Cytochrome P450 and ABCB1 genetics: association with quetiapine and norquetiapine plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia. A pilot study..J Psychopharmacol2011;25:896-907

[41] PiatkovI,AssurY,CoelhoM.CYP2C19*17 protects against metabolic complications of clozapine treatment..World J Biol Psychiatry2017;18:521-7

[42] VoirolP,PorchetF,JanzerRC.Cytochrome P-450 activities in human and rat brain microsomes..Brain Res2000;855:235-43

[43] AgúndezJA,MartínezC,BenítezJ.Modulation of CYP1A2 enzyme activity by indoleamines: inhibition by serotonin and tryptamine..Pharmacogenetics1998;8:251-8